Boston Scientific Corp Stock EBITDA

BSX Stock

USD 89.25 0.75 0.83%

Boston Scientific Corp fundamentals help investors to digest information that contributes to Boston Scientific's financial success or failures. It also enables traders to predict the movement of Boston Stock. The fundamental analysis module provides a way to measure Boston Scientific's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Boston Scientific stock.

		Last Reported	Projected for Next Year
	EBITDA	3.5 B	3.6 B

EBITDA is likely to rise to about 3.6 B in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Boston Scientific Corp Company EBITDA Analysis

Boston Scientific's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Boston Scientific EBITDA

3.45 B

Most of Boston Scientific's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Boston Scientific Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Boston EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Boston Scientific is extremely important. It helps to project a fair market value of Boston Stock properly, considering its historical fundamentals such as EBITDA. Since Boston Scientific's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Boston Scientific's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Boston Scientific's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	0.94	0.5	0.89	0.94	0.77	0.83	0.1	0.59	0.78	0.66	0.87	0.9	-0.75	0.83	-0.45	0.77	0.69	0.79	-0.59	0.66	-0.03	0.66	0.87	0.8	0.7
Total Stockholder Equity	0.97		0.87	0.65	0.9	0.88	0.65	0.78	0.01	0.43	0.77	0.53	0.82	0.89	-0.65	0.81	-0.37	0.85	0.74	0.83	-0.49	0.6	-0.1	0.7	0.91	0.84	0.78
Net Debt	0.94	0.87		0.41	0.83	0.93	0.82	0.79	0.32	0.64	0.84	0.65	0.87	0.82	-0.78	0.77	-0.55	0.64	0.69	0.69	-0.66	0.74	0.17	0.51	0.82	0.71	0.56
Retained Earnings	0.5	0.65	0.41		0.59	0.3	0.05	0.3	-0.13	-0.31	0.57	-0.23	0.4	0.46	-0.12	0.4	-0.18	0.71	0.78	0.66	-0.07	0.36	-0.16	0.6	0.79	0.72	0.69
Accounts Payable	0.89	0.9	0.83	0.59		0.89	0.58	0.7	0.12	0.3	0.85	0.52	0.72	0.79	-0.74	0.78	-0.52	0.82	0.69	0.85	-0.67	0.58	-0.02	0.64	0.86	0.77	0.8
Net Receivables	0.94	0.88	0.93	0.3	0.89		0.76	0.73	0.27	0.67	0.77	0.75	0.76	0.83	-0.76	0.8	-0.46	0.67	0.52	0.7	-0.7	0.57	0.14	0.43	0.73	0.6	0.64
Total Liab	0.77	0.65	0.82	0.05	0.58	0.76		0.92	0.25	0.84	0.59	0.85	0.9	0.83	-0.78	0.82	-0.56	0.35	0.55	0.58	-0.58	0.62	0.09	0.48	0.6	0.58	0.29
Total Current Assets	0.83	0.78	0.79	0.3	0.7	0.73	0.92		0.1	0.62	0.68	0.75	0.93	0.89	-0.82	0.89	-0.54	0.59	0.72	0.8	-0.58	0.71	-0.06	0.75	0.77	0.81	0.53
Short Term Debt	0.1	0.01	0.32	-0.13	0.12	0.27	0.25	0.1		0.28	0.51	0.13	-0.01	0.08	-0.17	0.09	-0.23	-0.18	-0.11	-0.03	-0.28	0.22	0.97	-0.24	0.02	-0.12	-0.1
Intangible Assets	0.59	0.43	0.64	-0.31	0.3	0.67	0.84	0.62	0.28		0.27	0.86	0.61	0.61	-0.52	0.55	-0.29	0.05	0.1	0.18	-0.38	0.3	0.19	0.07	0.22	0.16	0.01
Short Term Investments	0.78	0.77	0.84	0.57	0.85	0.77	0.59	0.68	0.51	0.27		0.37	0.66	0.68	-0.68	0.66	-0.62	0.66	0.67	0.73	-0.66	0.77	0.38	0.58	0.81	0.74	0.61
Common Stock	0.66	0.53	0.65	-0.23	0.52	0.75	0.85	0.75	0.13	0.86	0.37		0.68	0.7	-0.73	0.72	-0.45	0.3	0.25	0.47	-0.63	0.42	-0.02	0.28	0.34	0.33	0.3
Long Term Debt	0.87	0.82	0.87	0.4	0.72	0.76	0.9	0.93	-0.01	0.61	0.66	0.68		0.88	-0.79	0.85	-0.58	0.61	0.83	0.76	-0.57	0.73	-0.17	0.72	0.84	0.83	0.51
Good Will	0.9	0.89	0.82	0.46	0.79	0.83	0.83	0.89	0.08	0.61	0.68	0.7	0.88		-0.64	0.95	-0.42	0.66	0.72	0.82	-0.47	0.54	-0.04	0.63	0.81	0.75	0.64
Treasury Stock	-0.75	-0.65	-0.78	-0.12	-0.74	-0.76	-0.78	-0.82	-0.17	-0.52	-0.68	-0.73	-0.79	-0.64		-0.69	0.58	-0.55	-0.54	-0.66	0.84	-0.72	0.03	-0.61	-0.65	-0.68	-0.45
Property Plant Equipment	0.83	0.81	0.77	0.4	0.78	0.8	0.82	0.89	0.09	0.55	0.66	0.72	0.85	0.95	-0.69		-0.45	0.68	0.72	0.87	-0.54	0.5	-0.04	0.56	0.79	0.72	0.68
Current Deferred Revenue	-0.45	-0.37	-0.55	-0.18	-0.52	-0.46	-0.56	-0.54	-0.23	-0.29	-0.62	-0.45	-0.58	-0.42	0.58	-0.45		-0.27	-0.48	-0.4	0.71	-0.64	-0.11	-0.41	-0.47	-0.49	-0.17
Net Tangible Assets	0.77	0.85	0.64	0.71	0.82	0.67	0.35	0.59	-0.18	0.05	0.66	0.3	0.61	0.66	-0.55	0.68	-0.27		0.71	0.85	-0.45	0.57	-0.27	0.65	0.83	0.82	0.87
Long Term Debt Total	0.69	0.74	0.69	0.78	0.69	0.52	0.55	0.72	-0.11	0.1	0.67	0.25	0.83	0.72	-0.54	0.72	-0.48	0.71		0.85	-0.38	0.68	-0.24	0.76	0.92	0.89	0.68
Capital Surpluse	0.79	0.83	0.69	0.66	0.85	0.7	0.58	0.8	-0.03	0.18	0.73	0.47	0.76	0.82	-0.66	0.87	-0.4	0.85	0.85		-0.54	0.59	-0.16	0.76	0.89	0.86	0.91
Deferred Long Term Liab	-0.59	-0.49	-0.66	-0.07	-0.67	-0.7	-0.58	-0.58	-0.28	-0.38	-0.66	-0.63	-0.57	-0.47	0.84	-0.54	0.71	-0.45	-0.38	-0.54		-0.62	-0.13	-0.37	-0.49	-0.46	-0.41
Long Term Investments	0.66	0.6	0.74	0.36	0.58	0.57	0.62	0.71	0.22	0.3	0.77	0.42	0.73	0.54	-0.72	0.5	-0.64	0.57	0.68	0.59	-0.62		0.06	0.65	0.67	0.75	0.41
Short Long Term Debt	-0.03	-0.1	0.17	-0.16	-0.02	0.14	0.09	-0.06	0.97	0.19	0.38	-0.02	-0.17	-0.04	0.03	-0.04	-0.11	-0.27	-0.24	-0.16	-0.13	0.06		-0.36	-0.1	-0.25	-0.18
Cash And Equivalents	0.66	0.7	0.51	0.6	0.64	0.43	0.48	0.75	-0.24	0.07	0.58	0.28	0.72	0.63	-0.61	0.56	-0.41	0.65	0.76	0.76	-0.37	0.65	-0.36		0.78	0.92	0.6
Net Invested Capital	0.87	0.91	0.82	0.79	0.86	0.73	0.6	0.77	0.02	0.22	0.81	0.34	0.84	0.81	-0.65	0.79	-0.47	0.83	0.92	0.89	-0.49	0.67	-0.1	0.78		0.94	0.77
Net Working Capital	0.8	0.84	0.71	0.72	0.77	0.6	0.58	0.81	-0.12	0.16	0.74	0.33	0.83	0.75	-0.68	0.72	-0.49	0.82	0.89	0.86	-0.46	0.75	-0.25	0.92	0.94		0.69
Capital Stock	0.7	0.78	0.56	0.69	0.8	0.64	0.29	0.53	-0.1	0.01	0.61	0.3	0.51	0.64	-0.45	0.68	-0.17	0.87	0.68	0.91	-0.41	0.41	-0.18	0.6	0.77	0.69

Click cells to compare fundamentals

Boston EBITDA Historical Pattern

Today, most investors in Boston Scientific Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Boston Scientific's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's ebitda growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Boston Scientific ebitda as a starting point in their analysis.

Boston Scientific EBITDA

Timeline

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Boston Scientific

Ebitda Over Time

Boston Ebitda

Ebitda

3.63 Billion

At this time, Boston Scientific's EBITDA is fairly stable compared to the past year.

According to the company disclosure, Boston Scientific Corp reported earnings before interest,tax, depreciation and amortization of 3.45 B. This is 293.53% higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 11.43% higher than that of the company.

Boston EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Boston Scientific's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Boston Scientific could also be used in its relative valuation, which is a method of valuing Boston Scientific by comparing valuation metrics of similar companies.

Boston Scientific is currently under evaluation in ebitda category among its peers.

Boston Scientific ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Boston Scientific's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Boston Scientific's managers, analysts, and investors.

Environmental

Governance

Social

Boston Scientific Institutional Holders

Institutional Holdings refers to the ownership stake in Boston Scientific that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Boston Scientific's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Boston Scientific's value.

		Shares
Dz Bank Ag Deutsche Zentral-genossenschaftsbank Frankfurt Am Main	2024-09-30	21.8 M
Capital World Investors	2024-09-30	21.7 M
Bollard Group Llc	2024-06-30	21.7 M
Hhg Plc	2024-06-30	18.3 M
Norges Bank	2024-06-30	17.9 M
Franklin Resources Inc	2024-09-30	15.9 M
Amundi	2024-06-30	15.4 M
Bank Of New York Mellon Corp	2024-06-30	14.8 M
Legal & General Group Plc	2024-06-30	13.9 M
Fmr Inc	2024-09-30	135.2 M
Vanguard Group Inc	2024-09-30	131.3 M

Boston Fundamentals

	Return On Equity	0.0892
	Return On Asset	0.049
	Profit Margin	0.11 %
	Operating Margin	0.17 %
	Current Valuation	140.3 B
	Shares Outstanding	1.47 B
	Shares Owned By Insiders	0.17 %
	Shares Owned By Institutions	92.48 %
	Number Of Shares Shorted	12.91 M
	Price To Earning	107.05 X
	Price To Book	6.35 X
	Price To Sales	8.27 X
	Revenue	14.24 B
	Gross Profit	8.68 B
	EBITDA	3.45 B
	Net Income	1.59 B
	Cash And Equivalents	928 M
	Cash Per Share	0.24 X
	Total Debt	9.49 B
	Debt To Equity	0.51 %
	Current Ratio	1.45 X
	Book Value Per Share	14.05 X
	Cash Flow From Operations	2.5 B
	Short Ratio	1.91 X
	Earnings Per Share	1.21 X
	Price To Earnings To Growth	1.62 X
	Target Price	97.0
	Number Of Employees	48 K
	Beta	0.8
	Market Capitalization	131.54 B
	Total Asset	35.14 B
	Retained Earnings	819 M
	Working Capital	1.58 B
	Current Asset	1.21 B
	Current Liabilities	923 M
	Net Asset	35.14 B

About Boston Scientific Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Boston Scientific Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Boston Scientific using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Boston Scientific Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Boston Stock Analysis

When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC